Genotoxicity of agaritine in the lacI transgenic mouse mutation assay: evaluation of the health risk of mushroom consumption.
The mutagenic potency of the common mushroom Agaricus bisporus and crude agaritine extracted from mushrooms was determined in vivo using a new mutagenesis assay with lacI transgenic mice (Big Blue mice). Pairs of female lacI mice were fed one of three diets for 15 wk: (1) fresh mushrooms 3 days/wk followed by normal lab chow for 4 days/wk; (2) freeze-dried mushrooms mixed at 25% (w/w) into powdered chow; or (3) a mushroom extract containing 30% agaritine (w/w) mixed into powdered chow. The corresponding daily doses of agaritine were 30 (averaged over the whole week), 80 and 120 mg/kg body weight, respectively. Positive control animals received N-nitrosodimethylamine, N-nitrosomethylurea or urethane, mixed into powdered chow at concentrations corresponding to daily doses of 0.3, 3 and 130 mg/kg body weight, respectively. DNA of the forestomach, kidney, liver, lung and glandular stomach of the lacI mice was examined for increases in mutant frequency (MF). Control MFs ranged from 5 x 10(-5) to 10 x 10(-5). Positive control substances induced a two- to seven-fold increase in MF in their respective target organs. Of the mushroom diets, significant effects were seen only with the crude agaritine extract: it induced an increase in MF of 100% in the kidney and 50% in the forestomach. The other two A. bisporus diets, with lower agaritine doses, showed slightly but not significantly, raised MF values in the kidney alone. Thus, agaritine was weakly genotoxic in vivo; no genotoxic activity other than that attributable to agaritine was detected in A. bisporus. Substances or processes that might influence carcinogenicity by means of non-genotoxic mechanisms (e.g. increase in fibre, or decrease in calorie intake) are not detected in the lacI assay. Using a previously derived quantitative correlation between mutagenicity in the lacI test and carcinogenic potency, the carcinogenicity of agaritine in mushrooms was estimated: the average Swiss mushroom consumption of 4 g/day would be expected to contribute a lifetime cumulative cancer risk of about two cases per 100,000 lives.
Shephard
S E
SE
Swiss Federal Institute of Technology, Schwerzenbach.
Gunz
D
D
Schlatter
C
C
D000364:Agaricus; D000818:Animals; D001426:Bacterial Proteins / Q000235:genetics; D004247:DNA / Q000187:drug effects / Q000378:metabolism; D004249:DNA Damage / Q000235:genetics; D029968:Escherichia coli Proteins; D005260:Female; D005506:Food Contamination; D005511:Food Handling; D005753:Gastric Mucosa / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects / Q000235:genetics; D007668:Kidney / Q000187:drug effects / Q000378:metabolism; D056968:Lac Repressors; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008168:Lung / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic; D009145:Mushroom Poisoning / Q000235:genetics*; D009152:Mutagenicity Tests; D009154:Mutation / Q000235:genetics*; D010659:Phenylhydrazines / Q000378:metabolism / Q000633:toxicity*; D012097:Repressor Proteins / Q000235:genetics; D012307:Risk Factors; D013270:Stomach / Q000187:drug effects
D001426:Bacterial Proteins; D029968:Escherichia coli Proteins; D056968:Lac Repressors; D010659:Phenylhydrazines; D012097:Repressor Proteins; D004247:DNA; C015654:agaritine